S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:FRLN

Freeline Therapeutics (FRLN) Stock Price, News & Analysis

$6.48
0.00 (0.00%)
(As of 02/20/2024)
Today's Range
$6.48
$6.48
50-Day Range
$6.37
$6.49
52-Week Range
$2.11
$8.74
Volume
N/A
Average Volume
12,055 shs
Market Capitalization
$28.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.13
FRLN stock logo

About Freeline Therapeutics Stock (NASDAQ:FRLN)

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

FRLN Stock Price History

FRLN Stock News Headlines

Acquisition of Freeline by Syncona Becomes Effective
Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
Acquisition of Freeline by Syncona Becomes Effective
Freeline Shareholders Approve Acquisition by Syncona
Freeline Therapeutics Holdings plc (FRLN)
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Syncona Limited to Acquire Freeline Therapeutics
FRLN Freeline Therapeutics Holdings plc
Freeline Therapeutics Holdings PLC ADR FRLN
Where Freeline Therapeutics Stands With Analysts
See More Headlines
Receive FRLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Freeline Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
3/28/2024
Next Earnings (Estimated)
4/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:FRLN
Fax
N/A
Employees
152
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.13
High Stock Price Target
$30.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+71.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$-88,970,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$12.07 per share

Miscellaneous

Free Float
4,259,000
Market Cap
$28.12 million
Optionable
Not Optionable
Beta
0.66
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Michael J. Parini J.D. (Age 49)
    CEO & Executive Director
    Comp: $2.16M
  • Mr. Paul M. Schneider (Age 53)
    CFO & Director
  • Dr. Henning R. Stennicke Ph.D. (Age 56)
    Chief Scientific Officer
  • Ms. Nicole Jones SPHR (Age 53)
    Chief People Officer
  • Mr. James Bircher (Age 56)
    Chief Technical Operations Officer
  • Dr. Pamela Foulds M.D. (Age 54)
    Chief Medical Officer
  • Ms. Naomi Aoki
    Senior Vice President of Corporate Communications & Investor Relations
  • Ms. Amy J. Spandau (Age 49)
    Interim Head of Finance

FRLN Stock Analysis - Frequently Asked Questions

Should I buy or sell Freeline Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Freeline Therapeutics in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FRLN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FRLN, but not buy additional shares or sell existing shares.
View FRLN analyst ratings
or view top-rated stocks.

What is Freeline Therapeutics' stock price target for 2024?

3 brokers have issued 12-month price objectives for Freeline Therapeutics' stock. Their FRLN share price targets range from $3.00 to $30.00. On average, they predict the company's stock price to reach $11.13 in the next twelve months. This suggests a possible upside of 71.7% from the stock's current price.
View analysts price targets for FRLN
or view top-rated stocks among Wall Street analysts.

How have FRLN shares performed in 2024?

Freeline Therapeutics' stock was trading at $6.37 on January 1st, 2024. Since then, FRLN shares have increased by 1.7% and is now trading at $6.48.
View the best growth stocks for 2024 here
.

When is Freeline Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 2nd 2024.
View our FRLN earnings forecast
.

How were Freeline Therapeutics' earnings last quarter?

Freeline Therapeutics Holdings plc (NASDAQ:FRLN) posted its quarterly earnings data on Tuesday, November, 9th. The company reported ($12.90) EPS for the quarter, topping the consensus estimate of ($15.20) by $2.30.

When did Freeline Therapeutics' stock split?

Freeline Therapeutics shares reverse split on Friday, May 12th 2023. The 1-15 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Freeline Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Freeline Therapeutics investors own include Adobe (ADBE), BigCommerce (BIGC), Checkmate Pharmaceuticals (CMPI), CVS Health (CVS), Old Dominion Freight Line (ODFL), Oak Street Health (OSH), Rocket Companies (RKT), Shopify (SHOP), Zoom Video Communications (ZM) and Zymeworks (ZYME).

When did Freeline Therapeutics IPO?

Freeline Therapeutics (FRLN) raised $126 million in an initial public offering on Friday, August 7th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Morgan Stanley and Evercore ISI acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Freeline Therapeutics' major shareholders?

Freeline Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include UBS Group AG (2.29%), Blue Owl Capital Holdings LP (2.00%), PenderFund Capital Management Ltd. (1.39%), Harbor Capital Advisors Inc. (0.47%) and Sphera Funds Management LTD. (0.38%).

How do I buy shares of Freeline Therapeutics?

Shares of FRLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FRLN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners